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Abstract Rheumatoid arthritis (RA) is a chronic, inflamma-
tory, progressive disease characterized by inflammation of the
synovial tissue. It results in the severe functional deterioration
of the joints involved and the incapacity to work. Our main
aim is to determine the characteristics of the current health-
care models used in treating rheumatoid arthritis patients in
Latin America. We want to analyze the details, using them as
the foundation to create an ideal health-care model that is
focused on the patient. We have revised documents, including
guides to clinical practice, monitoring models and health-care
models according to the current policies and resources avail-
able in various Latin American countries. Based on this infor-
mation, the qualities and deficiencies of the current models
will be analyzed, in order to use this as a basis on which to
construct a proposed health-care model that covers the specif-
ic needs of rheumatoid arthritis patients, considering the re-
sources of each population. Despite the collapse seen in many
health systems throughout history, we can learn from them
and should develop a new model starting from the path pur-
sued, capitalizing on our experiences, teachings, and errors
committed. However, in most cases, the obstacles to the suc-
cess of the systems do not lie in the fundamental structure or
the “spirit of the legislator” but rather in the day-to-day
development within the community and the special interest
of each agent in a system.
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Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory, pro-
gressive disease characterized by inflammation of the synovial
tissue. It results in the severe functional deterioration of the
joints involved and the incapacity to work. It is the most fre-
quently seen inflammatory rheumatic disease and can involve
other organs, aside from joints, including the lungs, heart,
eyes, skin, and vessels. Its diagnosis is eminently clinical [1].
If a good therapeutic result is not obtained, it causes major
progressive musculoskeletal disability. It is estimated that RA
patients die between 8 and 12 years earlier than the general
population; the primary cause of death in these patients is
cardiovascular disease and arteriosclerotic events in 40 %.
The cost of its impact on public health is comparable with that
of heart disease [2].
The quality of life related to health (evaluated by DAS28)
in RA patients is poor and comparable with that of patients
suffering from chronic diseases. Rheumatic diseases are of
high impact and thus require close attention. The differences
mainly lie, as compared with other chronic diseases such as
diabetes mellitus and chronic kidney disease, in the perception
of pain and disability, which is greater in rheumatic disease
groups [3].
Recent literature reveals that an early, and sometimes ag-
gressive, approach to the pathology can significantly alter the
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clinical progression of the disease. Unfortunately, the health-
care model in Latin American countries is based on the clas-
sification of institutions according to levels of complexity
(generally classifying from level I to level III or IV, with I
being the least complex and III or IV, the most specialized).
This typical classification of services fragments the health-
care model, ignoring the dynamics that arise in a model that
is focused on the patient and their disease. In turn, this limits
the appropriate attention and correct treatment by specialists
during early stages of disease [4].
In the current model, following an external consultation or
induced-demand consultation, most patients are directed to-
wards promotion and prevention programs. At this point,
however, the patient requires studies and specialized rheuma-
tology care in order to be suitably classified, diagnosed, and
treated. As a product of the current health systems, barriers
begin to appear along the long journey before finally benefit-
ing from treatment that is capable of changing the course of
the disease [5].
A model therefore appears where the patient is the focus,
which should be introduced and applied to Latin American
health systems for the treatment of patients with chronic dis-
eases. Disease management (DM) can be defined as a process
to optimize public services by coordinating resources through-
out the health system, during the entire disease life cycle. It is
based on scientific evidence and aims to improve quality and
results (clinical, economic, quality of life, and satisfaction of
users and professionals) at the lowest possible cost. The es-
sential aim of disease management programs is to limit the
long-term costs on the health system. A fundamental part of
this new public service philosophy is the “revolution” of the
scale of priorities and values between medical professionals.
A move is made away from a system that is based and focused
on solving acute pathologies and problems and towards a
system based on the prevention and management of chronic
diseases and conditions. It heads away from a system where
professionals and managers and their interests and corporate
limitations play a key role, towards one in which it is the
patients and the organization of their treatment that take the
lead [6].
Barriers preventing access to health care
in the current health-care model
Prohibitive costs
RA has direct, indirect, and intangible costs. Direct costs in-
clude medical and paramedical attention, treatment and diag-
nostic procedures, hospitalization, early retirement, etc. [5].
Indirect costs include loss of productivity and reduced in-
come. Intangible costs include all those relating to the deteri-
oration of patient quality-of-life [5, 7].
It should be noted that the main element of the direct med-
ical costs of RA are the costs of the drugs or medicines that,
together with scientific progress, have reduced mortality, mor-
bidity, and disability considerably, yet the secondary cost to
the use of new medications has risen [7, 8].
For example, in Colombia, the monthly cost of patient care
comes to approximately US$ 1000 of which medications ac-
count for approximately 87.9 % of the relative net cost. This
ends up generating higher costs for caring for patients with
cardiovascular disease and a great many other entities typical-
ly considered as high-cost diseases [5].
InMexico, it is estimated that RA has a prevalence of 1.6%
and mainly affects the age group with the greatest capacity to
work and produce. This is therefore then reflected in high
levels of working disability and disability pensions, which
have an equally high impact on the economy. It is estimated
that the direct medical cost in dollars of RA in Mexico is US$
2334, and the cost from the patient’s own pocket is US$ 610.
Reports have revealed that 15 % of the family income goes
towards RA expenses, which can be disastrous on the
economy of any family [9].
In Mexico, the annual cost of the care for a patient with RA
is US$ 5534 (65 % direct costs and 35 % indirect costs). It has
been seen that in 46.9 % of RA patients, the costs from the
disease to be covered generate expenses against the household
income. Together with a retrospective analysis, mainly con-
sidering the type of insurance cover offered and the duration
of the disease, results in the impoverishment of 66.8 % of
households, associated with catastrophic costs. The cost
of RA in Mexican homes and particularly in those with-
out full health coverage results in catastrophic costs and
impoverishment [10].
Inadequate consideration of the “high cost”
In Colombia, which today has 96 % of the population covered
by insurance, a definition has been established of “ruinous or
catastrophic” diseases. This definition sought to ensure a spe-
cific approach to these diseases, with two aims: to protect the
individual by exonerating him or her from the payment of
deductibles or co-payments and, the other, to ensure the sus-
tainability of the system, starting from the compulsory pay-
ment of contributions for at least 2 years. However, this model
has been violated by lawsuits, adverse selection, and other
phenomena that have seriously threatened its sustainability.
This results in an effective risk to the future protection of
patients and, in particular, the lack of alignment of the objec-
tives of insurers and patients: there is no clear incentive in the
model to generate an impact on health and improve patient
condition. In other health models, such as the case of Peru, for
example, there is nomodel that ensures universal financing for
the high cost and treatment of the disease. Indeed, there is only
a low level of insurance coverage (61.8 %) with close to
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11 million people (38.2 % of the population) unprotected. The
disease is considered as part of a fragmented model according
to levels of complexity [5, 11].
Additionally, the definition of “ruinous or catastrophic dis-
eases” paradoxically automatically excluded diseases like
rheumatoid arthritis, whose health-care costs during a patient’s
lifetime well exceed the costs of a coronary angioplasty or
other diseases that receive greater attention by the different
system agents [1, 5]. The classification of the disease as “ru-
inous”must therefore take a patient focus. It should mean that
payment of sliding scale fees and co-payments should be ex-
empt in diseases such as rheumatoid arthritis, high blood pres-
sure, or asthma. A restriction should be applied to accessing
health services where the decision is made by the health-care
professional and not by the patient.
The idea behind co-payment is to co-finance the sys-
tem by the user, and the sliding scale fee seeks to ra-
tionalize the use. Given that in RA, services are used
frequently and restricting access to such would forms a
barrier, the financing of health care must be insured
through risk premiums and not in the form of co-
financing by patients. The concept must be that no ad-
ditional charges shall be demanded of the already neg-
ligible resources of the insurers but rather the relevant
adjustment will be made in the Per Capitation Unit
(PCU) ensuring access and attention to those suffering
from chronic diseases like RA.
System fragmentation and deficiency of specialized
networks and centers of excellence
The health-care model in Latin American countries is based
on the classification of institutions according to levels of com-
plexity (generally classifying from level I to level III or IV,
with I being the least complex and III or IV, the most special-
ized). This typical classification of services fragments the
health-care model, ignoring the dynamics that arise in a model
that is focused on the patient and their disease [4, 11].
Clearly, we cannot demand that the RA health-care model
should have specialized doctors, given that we have already
reported on the insufficient number of such and the critical
supply/demand ratio in this respect. Indeed, the needs of the
major cities can simply not be met, and the supply is simply
non-existent throughout much of national territory. The con-
cept of “coordination” implicit in the model described, and
which will be detailed further on, can be potentially redeemed.
Limited supply of services
The lack of appropriate services for the disabled is an impor-
tant barrier that prevents access to health care. For example,
investigations carried out in the states of Uttar Predesh and
Tamil Nadu, in India, revealed that after cost, the lack of
services was the second most important barrier to the use of
medical establishments [7].
Physical obstacles
Rheumatoid arthritis affects 1 % of the population and is more
frequently the cause of disability than heart disease, cancer, or
diabetes mellitus. Unequal access to building (hospitals,
health centers), an inaccessible medical equipment, poor sign-
age, narrow doors, indoor stairs, inadequate bathrooms, and
inaccessible parking areas all create obstacles to the use of
health-care structures [7].
The accessibility of health and transport services are two of
the main reasons why the disabled simply do not receive the
care they need in low-income countries: 32 to 33% of the non-
disabled population cannot afford health care, as compared
with 51 to 53 % of disabled people.
Inadequate skills and knowledge by medical staff
The disabled report a lack of skills among medical staff in
attending their needs, twice as often as the non-disabled. They
report mistreatment by said staff four times as often and that
care is denied to them, three times as often [7].
The aim of early treatment with disease-modifying anti
rheumatic drugs (DMARDs) in patients with RA is to sup-
press the activity of the disease before it causes joint damage.
This allows for a better prognosis and potentially results in the
remission of the disease for patients who start treatment during
the first 3 months. In turn, this results in a lesser risk of dis-
ability and incapacity 5 years down the line.
One clear example that reveals the insufficient knowledge
about the disease, and thus the ability to identify it in a first
consultation and make an early diagnosis, is seen in a study
carried out on 98 patients in Mexico in 2010. This found that
only 19 % of patients started DMARDs during the first
3 months from when symptoms began. The delay in prescrib-
ing DMARDs was caused mainly by the delay in the GP
referring the patient to a rheumatologist. Clearly, the late di-
agnosis of RA, long after symptoms start, is also a contribut-
ing factor in the delayed start of treatment with DMARDs.
Studies conducted in the last 20 years on the start of treatment
with DMARDs in patients with early onset of RA in the Unit-
ed States of America [12], Spain [13], Canada [14], England
[15], the Middle East [16], and other European countries [17]
show that the average time between the start of symptoms and
the start of DMARDs varies between 6 and 18months, similar
to that seen in the Mexican study (average 11 months). There-
by, less than 30 % of RA patients receive treatment with
DMARDs during the first 3 months [18–20]. This is why it
is important to create strategies that impact the diagnosis of
RA and the early start of treatment with DMARDs [21–23].
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Special considerations for Latin America
There are insufficient qualified people able to treat rheuma-
toid arthritis. The World Health Organization (WHO) has
established that there must be at least one rheumatology spe-
cialist for every 100,000 inhabitants, and this is a long way off
current standards. Indeed, in view of the current deficit in
specialized human resources, PANLARhas agreed to improve
the diagnostic and therapeutic capacity by involving GPs in a
critical drive made by society to improve the quality of the
population of patients with the disease [17].
Lack of availability of medications and access to therapies.
Currently recommended RA treatments are very expen-
sive. In Argentina, they can cost up to 89 % of the
average lifetime income of the population, and this
comes in addition to the problems relating to education,
poverty, and lack of health, making access very prob-
lematic in this context [17].
Inadequate information systems and insufficient medical
records. Another means by which to improve the identifica-
tion of RA is to optimize the systems used to record data in
medical records. Effective records containing essential data on
epidemiology, standardized forms using CIE-10 codes, de-
mography, employment, absenteeism from work, days of dis-
ability, cause of death, and other such information can in fact
allow for the early identification, monitoring, and prevention
of complications [17].
Characteristics of a patient-focused health-care
model
The characteristics of an ideal health model should be
determined according to the needs and resources of the
population in which it is to be applied. However, there
are always shared objectives to be met, such as the
following [11, 24]:
& Equality in accessing health care
& Continuity of medical attention and treatment
& Completeness of the service provided
& Effectiveness
& Joint responsibility of the medical team, insurer or financ-
ing party, and patient and their family.
& Inter-cultural nature
& Empowerment of the community and patient
& Social discussion: that debate on the financing of the dis-
ease and the sustainability of the model must be open and
the society must make the investments required. What
should be included and excluded in and from a benefits
plan? Where should investments be made and not be
made? Individual ethics vs. collective ethics
& Humanization
& Patient safety
& Focus on health results: patient safety, survival, impact in
terms of disability, and disease progression.
& Satisfaction: patient expectations must be met. The model
must consider the establishment of objectives focused on
patient expectations with a view to optimizing the level of
reintegration in everyday activities. There must also be an
assessment of the degree to which patient expectations are
met by the treatment and health-care model. It is not a
question of achieving purely medical objectives, nor of
satisfying the specialist’s expectations, but rather those
of the patient, according to their values, priorities, and
the way in which they see life.
Proposed health-care model
In Colombia (as an example), the population has a
health system that covers preventive, curative, and reha-
bilitation care services. Despite this, however, a series
of aspects restrict actual coverage, creating a new real-
ity: the lack of protection of the population due to a
failure to align the interests and the model, despite the
universal coverage offered by the system.
Today, typically, “gateway” services operate in a cap-
itation method with populations assigned to a given
outpatient center. This model effectively restricts access
to specialists, whether included in the capitation or
brought about with the charge to the insurer following
referral. In either case, the model basically allows the
gateway to act as a sort of “gate keeper,” restricting
access to specialists, partly, of course, to cope with
the clear lack of professionals available. In some cases,
however, the approach instead stems from the misunder-
standing that leaving the patient in the hands of the GP
is rational. Yet early access to the specialist, hand-in-
hand with risk management assured through a properly
trained medical team in primary management, can re-
duce complications and disease progression. It can also
assure a more rational approach to the use of diagnostic
methods, less pointless doubling-up of such and phar-
macological prescriptions that are more in line with the
clinical situation and patient needs.
The proposal includes monitoring a patient according to
personal health risk and with a clear aim. The different levels
of complexity can be structured and a full, appropriate, spe-
cialized care assured, with no restriction to access, no co-pay-
ment, no deductible nor sliding scale fees that could potential-
ly restrict access to the services the patient needs and are
prescribed by the professional [2, 8].
In this way, the attention paid to high-cost chronic
diseases requires a “side flow” model. This therefore
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establishes the following pillars of the new disease man-
agement model:
1. Active search for cases and early identification.
This is why resources must be allocated to primary
health care to ensure that medical staff and the
community are made aware of the signs, symp-
toms, and criteria for pre-diagnosis. In turn, this
results in their empowerment, enabling them to
make suitable decisions in requesting qualified ser-
vices. Thereby, the active search for cases is one
of the pillars of the model’s success and takes into
account specific actions that aim to have patients
seeking consultation during the early stages of the
disease, when symptoms are still minor or of re-
cent onset.
These actions include the following:
(a) Training of the society on signs and symptoms. The
paradigm is who should do it? The government? On
what basis? The intervention of each of the
players and the sum total of efforts allow us
to become a more informed, more empowered
society. In this way, we can share examples of
individual efforts that generate awareness and a
transformation process. In Peru, Oncosalud, a
cancer protection institute with more than 700,
000 members and 25 years of experience, uses
its website and various social networks to per-
manently send messages about the prevention
of the disease. It gives recommendations on
healthy lifestyles, how to recognize early signs
of the disease, and self-examination techniques,
among others. It has even created a contest:
PREVENCE, which celebrated its third edition
in 2015. This includes a school category with
the aim of having Oncosalud process education-
al digital materials to get the school community
involved in developing strategies for dissemi-
nating prevention messages, ensuring they “go
viral,” rewarding the school and course with the
greatest impacted population. The winning
school and students obtain a prize in the form
of goods and tools to facilitate educational de-
velopment (tablets, computers, etc.). These
prizes are purchased by Oncosalud, which also
pays for the costs of the contest, the digital
materials and the logistics, and dissemination
of materials to the various schools. Once the
category was structured, it was presented to
the Ministry of Education and the Ministry of
Health, making the campaign a part of the cur-
ricular mesh developed jointly by the two
ministries. Although this strategy will provide
initial coverage, it must start empowering the
pediatric and general population from an early
age. Similar strategies are easily replicated for
community education.
(b) Revision of uses: insurance companies must continue
to reinforce a proactive position with regards to the
identification of risks. They do so by taking data
from their insured parties and implementing process-
es that revise uses, enabling the identification by
consultants of risk signs and symptoms, a more pro-
active position.
(c) Implementation of “Habitual Consultancy”
programs: Compensar, in Bogota, Colombia, has
implemented processes for monitoring and iden-
tifying populations seeking frequent consulta-
tions for similar reasons. The most complete
analysis of these populations, reasons for con-
sultation, and the directing of these individuals
to special, longer consultation makes it possible
to define the signs, symptoms, and any risks
obtain a precise diagnosis and guide the man-
agement of patients showing signs and symp-
toms of chronic diseases.
2. Insurers need to base care models on the assurance
of defined principles. If the network is not
accredited, attention should be delegated to an
accredited network. This allows insurers to high-
light minimum standards for the attention to pa-
tients with chronic diseases, in this case, RA pa-
tients. These should include the following: training
of staff and gateway professionals on RA, special-
ized support in the form of coaching; availability
of specialized staff to provide GPs with support,
either by a physical presence or remote medicine;
availability of databases enabling the monitoring
and identification of the population and the use
or care that facilitates the establishment of cohort
monitoring processes, optimal medical conditions,
safety of installations and equipment, infrastructural
conditions enabling all (including disabled) patient
access to centers, skilled, trained medical staff in
recognizing and managing rheumatic diseases; and
extensive knowledge of the route to be taken by
the patient, minimizing hindrances and obstacles to
save valuable time in affording the patient treat-
ment and encourage him to pursue it. The insurer
must have the resources to carry out clinical exam-
inations, provide medications and to teach and
train the patient on how to care for their disease.
Lastly, the insurer must have an internal entity in
charge of regulating due compliance with the na-
tional processes and protocols governing the
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management of RA patients and suitable manage-
ment of the resources assigned to them.
3. Implementation of the “revision of uses” process: the
role of the insurer clearly entails its liability for health
care and, therefore, the active search for cases must in-
volve the implementation of a process revising uses with
regards to certain parameters (consumption of medica-
tions, consultations for certain diagnosis of CIE 10, use
or prescription of certain laboratory tests, etc.). This is
why access to clinical and paraclinical information is
mandatory. The identification of potential cases must
be directed towards the network qualified to perform a
primary assessment.
4. Adoption of a trans-disciplinary health-care model
that runs alongside the gateway capitation model.
In this respect, and regardless of the method of
payment, any suspected patient should be assessed
early on by the trained team (a “case manager”).
Thus, when obtaining an approximate diagnosis,
the patient will be referred back to the gateway if
rejected at diagnosis or will have coordinated spe-
cialized attention if the diagnosis is confirmed or
looks to be highly likely. Starting from this point,
the attention process should follow on with special-
ized centers (treatment providers) in managing or
coaching in the cities and municipalities where
there is a lack of rheumatology specialists.
5. The implementation of remote medical services
granting access to specialists nationwide is essen-
tial. By using applications such as e-mail, fax, vid-
eo conferencing, and WebEx, as well as mobile
applications like WhatsApp, Viber, and Skype,
along with telephone calls, specialists like the
rheumatologist, radiologist, cardiologist, and phys-
iatrist can be consulted in primary or secondary
attention centers. The doctor therefore obtains more
information helping them make decisions, and
greater skills, effectively benefiting both the doctor
and patient alike. Moreover, in this model, remote
medicine becomes an essential tool for the patient.
Indeed, it enables constant, direct communication
with the doctor or medical staff, thereby settling
doubts, reinforcing healthy behavior and improving
adherence to treatment with no need to move from
their home or place of work.
6. The human resource medical training policy needs
to be revised, assigning resources to increase the
availability of specialties with a careful analysis of
supply and demand according to territory, region,
and city.
7. Redefinition of the benefits plan. The incorporation
of medical technologies, extensively discussed in
terms of the sustainability of the social security
systems, must also undergo major changes. There
must be an incorporation of drugs and technology
to satisfy the solid evidence with clear cost-effec-
tiveness, cost-benefits, cost-minimization studies,
among others, but the process must be defined
and coupled in such a way as to flow effectively.
Prescription under the protective figure, CTC, pro-
tective or other legal proceedings, significantly re-
duces the possibility of implementing clinical prac-
tice guides and disease management. The disease
should therefore clearly be managed strictly in ac-
cordance with clinical practice guides and the ther-
apeutic lines and scales defined therein.
8. The definition of a disease as being “ruinous” or
“catastrophic” must include entries such as rheu-
matoid arthritis, meaning that the non-application
of co-payments and sliding scale fees can success-
fully eliminate the access barrier that naturally fol-
lows in respect of a disease whose prescriptions,
procedures, and interventions are to a large extent
carried out in outpatient clinics, with the patient
paying for each of the services. The concept of
“sliding scale fees,” aiming to moderate use of
services decided by the patient, is a more complex
matter. It would often, in fact, appear to be rather
contradictory given that patient adherence to treat-
ment is required, their use of the preventive and
rehabilitation services, yet the application of slid-
ing scale fees to services means that the patient,
rather than the doctor, may say NO to such. In
this way, the concept to be applied would perhaps
be more appropriate as “co-payment,” as a co-
financing element, yet as already explained, this
must be exonerated and financing should be in-
volved in a first adjustment for risk following a
careful analysis so as to correct the effect on the
system's sustainability.
9. There must be a system to measure the process of
attention and assessment of management according
to outcomes by each of the insurers and/or quali-
fied networks to provide the services, incorporating
indicators with a patient focus. This will result in
an about-turn in the definition of “patient journey”
and the care process.
10. Regarding the previous point, it is also essential to
assess patient satisfaction with the level of resump-
tion of their day-to-day activities. The key objec-
tive of the model should be to maintain and pre-
serve patient satisfaction with their level of recov-
ery, classified as the degree to which they can re-
sume their everyday activities. What is truly impor-
tant in a health-care model adopted to deal with
chronic diseases is the quality of life achieved. It
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is not a question of adding “years to life,” but
rather “life to years.”
11. In the stages into which medical science breaks
down the process of recovery and the disease,
which unfortunately evolves towards a fatal out-
come and clearly limited function, the health sys-
tem and attention process must go hand-in-hand
with home assistance. This home assistance should
include pain management, infection management,
support with cardiovascular deficiencies, among
others, as well as ensuring the basic training of
caregivers. Said caregivers may be family members
or persons appointed by them, but in any case, it is
clear that the family takes primary responsibility
for caring for their loved ones and this basic, so-
cial, nutritional, and living care cannot be delegat-
ed, as the health system is only responsible for
medical treatments. We cannot allow for a model
where the families “abandon” patients to the mercy
of the health system, even if still at home. And,
therefore, the dissemination of a model of the
“rights and duties” of the users and caregivers, as
a condition for the patient’s admission to the dis-
ease management model, must involve the signing
and specific acceptance by these persons, even po-
tentially considering the application of “pedagogic
sanctions.”
12. Implementation of means intended to guarantee patient
safety throughout the health-care period [25]:
& The standardization of a system seeking out risk fac-
tors, failings, and adverse events.
& The suitable reporting of adverse events so that cor-
rective action can be taken to avoid new cases.
& The investigation, analysis, management, and
decision-making to avoid foreseeable adverse
events and, if such should arise, to mitigate
their consequences.
& The organization defines if the current care is the
consequence of an adverse event, regardless of
where the previous care was given.
& From access, redundant identification mechanisms
of the patient are defined.
& From access, the risks of care are identified,
according to the type of user. Said risks should
be recorded in a specific section of the medical
records, where all those involved in caring for
the patient can be warned to avoid adverse
events during their care.
13. The gateway of primary care is converted in this
model into the body that, as part of the care flow,
is responsible for initiating the other strategies, by
which, as described previously, the GP shall have
the information available to him to allow him to
feel sure about taking decisions with the patient
seeking their consultation. This information may
be supplied by: remote medicine applications en-
abling him to communicate with the rheumatologist
and other specialist doctors who can provide real-
time guidance on diagnosis and treatment if there
are any doubts; teleconferencing and video confer-
encing (again provided by specialists), such as ac-
ademic discussions involving current clinical prac-
tice guidelines regarding the population with which
they works. They shall also be granted access to
RA treatment protocols supplied by the insurer
when the doctor is contacted and thereafter
assessed in day-to-day practice in terms of their
correct application. All this facilitates good clinical
practice, reduces the probability of unnecessary re-
ferrals to specialists, thereby saving time and
resources.
14. When taking the patient into consideration, the
places where they or she receives medical attention
must be adjusted to overcome any accessibility ob-
stacles and ensure greater adherence to treatment.
This is why in caring for RA patients, health-care
centers or clinics must have the following
characteristics: wide access doors to allow wheel-
chairs in and the health-care center must have suf-
ficient chairs for patients and their caregivers and
potentially several members of family who may
attend the visit in a comfortable manner. Ideally,
there should also be a place to perform case his-
tories, which would be more like a visiting room
and have no barrier in the form of a large desk
separating the doctor from their patient. The center
should also have material to enable the doctor to
graphically explain the disease to the patient and
make sure their recommendations are fully under-
stood. The health-care center should also have the
following:
& An examination area
& Area separation barriers
& Medical unit
& Sinks
& Natural or artificial ventilation
& Natural or artificial lighting
The center should have the following equipment:
scale, blood pressure monitor, height rod, stethoscope,
meter ruler, hearing equipment, goniometer, x-ray view-
er, treatment trolley, lamp, stretcher, stepladder (with
two steps), desk, chairs, screen with two parts, filing
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cabinet, hospital waste containers with lid, and sharps
containers.
All these are basic requirements to guarantee suitable
patient care.
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POPULATION




EARLY ASSESSMENT BY A TEAM 
TRAINED IN RA
(Case Manager)
Confirmation of RA 
NO co-payment nor sliding 
scale fee
ATTENTION AND MONITORING OF THE 
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Elements necessary for handling RA as a chronic
medical condition
To develop the structures and processes that enable rheuma-
toid arthritis (RA) patients to reach stable conditions, to im-
prove or even go into remission of symptoms, as applicable,
and to keep the patient in these conditions [1, 8, 18, 20], in
these cases, the following elements are particularly critical:
1. Education and support in self-care, particularly in the com-
munity, at work, and in social settings in general. As part of
its promotion and prevention programs, each insurer shall
configure thismodel as an essential part of patient education,
empowering the patient with respect to their disease. Once
the patient has been diagnosed with rheumatoid arthritis,
they will automatically be included in their insurer’s school
of patients. Here, talks will be held by an interdisciplinary
group of medical professions (such as doctors, physiother-
apists, nutritionists, psychologists, and nurses) and by other
patients acting as positive examples in disease manage-
ment, on RA-related matters. These will generate support
in changing habits and adopting healthy lifestyles, such as
changes in working routines, dietary changes, and the im-
plementation of joint protection techniques. Virtual care
(by means of video conferencing) or physical attendance
of such activities must be compulsory for diagnosed pa-
tients. It shall therefore be a requirement for continuing the
program, receiving medication and benefiting from the ex-
emption from co-payment of care.
2. Support in changing habits and adopting healthy life-
styles, as well as making changes to working routines,
dietary changes, and the implementation of joint protec-
tion techniques.
3. Support and monitoring of adherence to pharmacological
and non-pharmacological therapy.
4. Patient contact with their personal doctor of the center
specialized in RA (treatment provider) in the event of
worsening or acute episodes.
5. Patient contact with their treatment provider to solve minor
day-to-day needs, using different contact methods such as
telephone, e-mail, text messages, chat, web and videos.
6. Implementation of remote medicine channels. For cities
or municipalities without rheumatology specialists, an ar-
ea must be set up with trained human resources. This can
therefore act as a specialized RA care center for these
populations, and the professionals will be tutored by the
rheumatologists and other specialists leading the program
by means of IT and communication tools [19].
7. To ensure the evaluation of the patient by rheumatology,
physiotherapy, and occupational therapy immediately fol-
lowing confirmation of a diagnosis of RA and according
to the patient's individual needs as recorded by their treat-
ment provider.
To use clinical management tools that successfully opti-
mize use of resources according to clinical results and quality
of life, such as:
1. Development and adoption of protocols for highly stan-
dardized processes and verification of strict application.
2. Development, adoption, and bringing up-to-date of clini-
cal practice guides for less standardized processes, verify-
ing their application and regularly analyzing possible
deviations.
3. Detailed monitoring of the indicators of clinical results
and quality of life and of the ways resources are used
and the relevant impact on the provider’s prospective
budget.
4. Individual patient monitoring by a team with extensive
knowledge of the disease, the available resources, pro-
cesses and objectives.
5. Implementation of improvement cycles in order to obtain
better clinical and economic results.
6. Unification of the medical history to keep all patient and
disease data together.
7. Medical committee or council to define biological
therapy [26].
To develop IT tools that can monitor internal processes,
patient communication with their provider and support remote
medicine communication channels between specialized and
non-specialized doctors, physiotherapists, nurses, and other
members of the team. These can run between different spe-
cialized care centers to guide patient management [26, 27].
Referral and counter-referral of RA patients
To achieve a suitable RA patient journey and optimize re-
sources, this model suggests that the RA patient should be
assessed by the specialist in: rheumatology, physiatry, and
occupational health, always in the following two cases:
1. Once the RA has been diagnosed on a first level or at
gateway, in compliance with the clinical and paraclinical
criteria assessed by the doctor according to the protocols
and clinical guides adopted by the Ministry of Health for
application throughout the national territory.
2. If the patient has any complications or clinical situations
that have not been successfully solved, despite the use of
all resources available by the first level treatment provider,
and which have proved to be insufficient, despite good
adherence by the patient to treatment, due to the complex-
ity of the case.
Referral to other supporting professionals (psychologist,
social worker, nutritionist, nurse) will be made according to
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the specific needs of each patient and as considered relevant
by the primary physician, at any time.
The rest of the consultations for optimizing and moni-
toring RA patients will be organized by the primary phy-
sician, the multidisciplinary team trained to manage these
types of patients. Tangible benefits will ensue for both the
patient and the health system, as patients living in rural
areas can be avoided the costs and inconveniences in-
volved in moving to 3rd or 4th level centers for special-
ized medical consults. Indeed, these roles are replaced by
the nearby GP (who knows the patient and their family)
and other professionals trained by the closest primary
medical center (treatment provider) to manage this type
of pathology. These professionals shall act under the di-
rection of a chief rheumatologist who will make remote
contact using the remote medicine applications explained,
avoiding months of waiting to see the specialist, as a
result of the severe lack of such and the great congestion
of the health system, which also affects adherence and
continuity of treatment and patient monitoring. It regu-
lates the costs of the health system, ensuring fewer
disease-related complications, and avoiding mass afflu-
ence of patients to the clinics and hospitals of greater
complexity [20, 26, 28].
ALGORITHM OF PATIENT HEALTHCARE WITH RECENT 
























PATIENT REFERRAL TO SPECIALIST
According to individual requirements and control of 
each paent
Center specialized in RA (treatment 
provider)
Includes medical staff
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Paent journey
Paent idenfying signs and 
symptoms of RA "Paent 
empowerment"
Paent seeking consultaon for 
any reason or for a medical check-
up
GP or primary care physician
Sees clinical signs and symptoms
of RAYes No
Management of a pathology other 
than RA
Order to carry out laboratory tests 
and imaging to support or reject 
the diagnosis of RA
Tests compable with diagnosis
of RA
Yes
No Search for diﬀerenal diagnosis
Diagnosis of RA
Paent referral to specialized 
doctor (rheumatologist, 
physiatrist, occupaonal health)
Establishmentof the RA 




Counter-referral to the primary 
caregiver with an 
interdisciplinary group trained 
on handling RA (Treatment 
provider)
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Indicators to mediate the results
Remission
Definition Percentage of people diagnosed with RA and
who are in remission after 12 months of
monitoring. Remission will be defined
according to EULAR criteria.
Calculation
Denominator Number of patients who have received a
diagnosis of RA.
Numerator Part of the denominator in remission.
Disability
Definition Percentage of people diagnosed with RA
who, as a result of the disease, suffer some
form of limitation to joint function.
Calculation
Denominator Number of patients who have received a
diagnosis of RA.
Numerator Number of patients suffering from some form
of limitation to joint function caused by the
disease (number of anatomical regions with
severe or limiting reduced function) or
number of days of working disability or of
days of functional disability.
Use of orthopedic surgery
Definition Percentage of patients diagnosed with RA
who have had surgery as compared with total
number of cases monitored.
Calculation
Denominator Patients who have received a diagnosis of RA
during monitoring.




The challenges faced by the systems in Latin America
have three separate dimensions: financing, service sup-
ply, and quality of services. Each of these spheres must
be developed in a harmonious, balanced manner. Prog-
ress has been made in various countries with regards to
financing, with combined public and private efforts
made, yet major contributions are still required to en-
sure universal coverage. As concerns quality of services,
there has been growing interest in health certification
and accreditation processes, inspection, auditing, and
control models, accreditation processes, patient safety
models, and other elements involved in the disease
management. Clearly, these are now starting to draw a
line towards a permanent route in the search for quality.
Finally, the development of the treatment infrastructure
requires not only the construction of the physical infra-
structure but also the training of the human resources.
In the countries of our region, this matter requires some
form of effort made by the states, private enterprise, the
world of academia, and the other players involved in
the health systems, so as to ensure that the population
can access specialized professionals in different areas of
our territories. These new professionals must ensure the
provision of services based on clear, solid principles of
rationality and relevance that can, over time, facilitate
the financial sustainability of the model. The structure
with trained health professional networks and primary
health-care models with health coaching, the monitoring
of cohorts, and other forms of managed care mecha-
nisms, take more effort than technology.
Finally, a change is required in the collective conscience
and an in-depth social debate that can prioritize and focus
resources, solving the conflict of individual ethics vs. collec-
tive ethics. Complete well-being cannot be assured, yet we can
work towards building a better society.
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Recommendaons for the implementaon of an ideal healthcare model for Rheumatoid 
Arthris paents
1. To establish policies that can ensure the acve search for cases and early idenﬁcaon of the signs and 
symptoms of the disease by doctors, on a primary care level, and by the populaon itself, through 
instrucons on how to recognize them.
2. To ensure the evaluaon of the paent for rheumatology, physiotherapy, occupaonal therapy 
immediately following conﬁrmaon of a diagnosis of RA.
3. The RA paent care process must run its course in centers that are specialized and run by 
rheumatologists, in the most far-reaching cies and municipalies and provinces. Where there is a lack of 
these specialists, the implementaon of remote medicine services enabling the treatment provider team 
of the primary treatment network (which must be at least a GP, a nurse and/or a physiotherapist trained 
in RA) acng under the direcon of the rheumatologist in the specialized centers of the cies, is essenal.
4. To combine the eﬀorts by all enes involved in providing the healthcare services, to eliminate all factors 
liming or restricng access to the opportunity to aend paents diagnosed with RA and to guarantee 
that the specialized aenon, delivery of medicines and/or services ﬂows without hindrance or delay that 
would otherwise facilitate disease progression.
5. Insurers need to base care models on the assurance of deﬁned principles. Indicators must be included 
that can control and measure the eﬀecveness of the strategies implemented to manage RA paents, 
based on established indicators. If the model is not accredited, care must be delegated to an accredited 
network, subcontracted by said insurer.
6. To procure paent contact with their treatment provider to solve minor day-to-day needs, reinforce 
treatment adherence and connuous care, using diﬀerent contact methods such as: telephone, e -mail, 
text messages, chat, web videos, etc.
7. To ensure the paent has suﬃcient knowledge of the disease to be able to take responsibility for 
managing it and become familiar with the resources available to control it.
8. Development and adopon of naonal protocols for highly standardized processes that are based on 
knowledge supplied by clinical pracce guides adapted to individual characteriscs and resources of the 
populaon. The paent can thus connue independently to manage their disease, regardless of their 
place of residence, and to achieve guidelines for medical staﬀ to standardized care aﬀorded these 
paents.
9. Development, adopon and bringing up-to-date of clinical pracce guides for less standardized processes.
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